The Official Journal of EuroPCR and the European Association of Percutaneous Coronary Interventions (EAPCI)

Interventions for valvular disease and heart failure

Adverse events and modes of failure related to the Impella percutaneous left ventricular assist devices: a retrospective analysis of the MAUDE database

EuroIntervention 2019;15:44-46. DOI: 10.4244/EIJ-D-18-01021

1. Section of Interventional Cardiology, MedStar Washington Hospital Center, Washington, DC, USA; 2. Cardiovascular Branch, Division of Intramural Research, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA
Introduction

Percutaneous left ventricular assist devices (pLVAD) are indicated to provide short-term mechanical circulatory support in patients with cardiogenic shock, acute myocardial infarction (AMI) with cardiogenic shock, and for high-risk percutaneous coronary intervention (HRPCI)1. The Impella® device (Abiomed Inc., Danvers, MA, USA) is a non-pulsatile microaxial flow pump that continuously propels blood from the left ventricle (LV) to the ascending aorta. The Impella system is placed retrogradely across the aortic valve under fluoroscopic guidance, with its inflow in the LV and outflow in the ascending aorta. The Impella platform consists of several different models that vary in calibre, ...

Sign in to read and download the full article

Forgot your password?
No account yet? Sign up for free!
Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com

Read next article
Bioprosthetic or native aortic scallop intentional laceration to prevent iatrogenic coronary artery obstruction. Part 1: how to evaluate patients for BASILICA